Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obexelimab in relapsing multiple sclerosis
NCT06564311Phase 2Active, not recruiting
- Sponsor
- Zenas BioPharma
- Start
- Aug 2024
- Primary completion
- Aug 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing Obexelimab with Placebo (2 arms). Primary endpoint: Cumulative Number of New Gadolinium-Enhancing T1 Hyperintense Lesions at 12 weeks. Started Aug 2024; status: active, not recruiting.
02
Drugs
obexelimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06564311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06564311.